Skip to main content

Welgus Howard G.'s Form 4 filing

Arcutis Biotherapeutics, Inc. (ARQT) · filed Sep 17, 2026

Accession no.
0001628280-26-062490
Filed
Sep 17, 2026, 4:06 PM ET
Trade date
Sep 15, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $114.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Welgus Howard G.CIK 0001801050Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 15, 2026Common StockMOption exerciseAcquired+822$6.52+$5,361.3337,297Direct
Sep 15, 2026Common StockMOption exerciseAcquired+1,019$7.51+$7,652.6938,316Direct
Sep 15, 2026Common StockMOption exerciseAcquired+2,255$8.63+$19,460.6540,571Direct
Sep 15, 2026Common StockSSaleDisposed−4,730$24.18−$114,371.435,841Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 15, 2026Common StockMOption exerciseDisposed−822$0.00$06,574Direct
Sep 15, 2026Common StockMOption exerciseDisposed−1,019$0.00$08,144Direct
Sep 15, 2026Common StockMOption exerciseDisposed−2,255$0.00$018,032Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)